Di-sulfide containing cell penetrating peptides and methods of making and using thereof
Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
1. A bicyclic peptide selected from the group consisting of:
or a pharmaceutically acceptable salt thereof,
wherein:
AA 1 , AA 2 , AA 3 , AA 4 , AA 5 , AA 6 , AA 7 , AA 8 , and AA 9 are each independently an amino acid, wherein at least two of AA 1 , AA 2 , AA 3 , AA 4 , AA 5 , AA 6 , AA 7 , AA 8 , and AA 9 are arginine and at least two of AA 1 , AA 2 , AA 3 , AA 4 , AA 5 , AA 6 , AA 7 , AA 8 , and AA 9 independently comprise a hydrophobic side chain;
m, n, p, and q are independently selected from 0 and 1;
X n is a cargo moiety comprising a peptide sequence having from 1 to 20 amino acids;
wherein each d is independently 1 or 2; and
wherein R 1 is OH, OR 2 , NHR 2 ; and R 2 is a alkyl, aryl, heteroaryl, amino acid, peptide sequence of 2 to 20 amino acid, detectable moiety, or solid support.
2. The bicyclic peptide of claim 1 , wherein the at least two amino acid which independently comprise a hydrophobic side chain are selected from the group consisting of glycine, phenylglycine, alanine, valine, leucine, isoleucine, norleucine, phenylalanine, tryptophan, naphthylalanine, proline, and combinations thereof, wherein the aromatic side chains on phenylglycine, phenylalanine, tryptophan, or naphthylalanine are each optionally substituted with a halogen.
3. The bicyclic peptide of claim 2 , wherein the at least two amino acid which independently comprise a hydrophobic side chain are independently selected from the group consisting of phenylalanine, naphthylalanine, and combinations thereof.
4. The bicyclic peptide of claim 1 , wherein the at least two amino acids which independently comprise a hydrophobic residue are consecutive amino acids.
5. The bicyclic peptide of claim 1 , wherein:
AA 1 is L-arginine;
AA 2 is L-arginine;
AA 3 is L-arginine;
AA 4 is L-naphthylalanine;
AA 5 is L-phenylalanine; and
m, n, p, and q, are each 0.
6. The bicyclic peptide of claim 1 , wherein:
AA 1 is L-phenylalanine;
AA 2 is L-naphthylalanine;
AA 3 is L-arginine;
AA 4 is L-arginine;
AA 5 is L-arginine;
m is 1 and AA 6 is L-arginine; and
n, p, and q are each 0.
7. The bicyclic peptide of claim 1 , wherein:
AA 1 is L-arginine;
AA 2 is L-arginine;
AA 3 is L-arginine;
AA 4 is L-arginine;
AA 5 is L-naphthylalanine;
m is 1 and AA 6 is L-phenylalanine; and
n, p, and q are each 0.
8. The bicyclic peptide of claim 1 , wherein at least three consecutive amino acids have alternating chirality.
9. The bicyclic peptide of claim 8 , wherein the at least three consecutive amino acids having alternating chirality are arginines.
10. The bicyclic peptide of claim 9 , wherein:
AA 1 is D-phenylalanine;
AA 2 is L-naphthylalanine;
AA 3 is L-arginine;
AA 4 is D-arginine;
AA 5 is L-arginine;
m is 1 and AA 6 is D-arginine; and
n, p, and q are each 0.
11. The bicyclic peptide of claim 9 , wherein:
AA 1 is D-phenylalanine;
AA 2 is L-naphthylalanine;
AA 3 is L-arginine;
AA 4 is D-arginine;
AA 5 is L-arginine;
m and n are each 1, and AA 6 is D-arginine and AA 7 is L-arginine; and
p and q are each 0.
12. The bicyclic peptide of claim 9 , wherein:
AA 1 is L-phenylalanine;
AA 2 is D-phenylalanine;
AA 3 is L-naphthylalanine;
AA 4 is L-arginine;
AA 5 is D-arginine;
m and n are each 1, and AA 6 is L-arginine and AA 7 is D-arginine; and
p and q are each 0.
13. The bicyclic peptide of claim 1 , wherein the peptide sequence in X n inhibits at least one protein-protein interaction.
14. The bicyclic peptide of claim 13 , wherein the protein-protein interaction is an interaction between a IκB-kinase (IKK) complex and a regulatory protein NF-κB essential modifier (NEMO).
15. The bicyclic peptide of claim 13 , wherein the peptide sequence in X n is an inhibitor against Ras, PTP1 B, Pin 1, Grb2 SH2, MDM2, or combinations thereof.
16. The bicyclic peptide of claim 1 , wherein the peptide sequence in X n is a wild-type peptidyl ligand or a peptide mimetic.
17. A method for delivering a therapeutic agent to cytoplasm of a cell, comprising administering a compound of claim 1 .
18. The compound of claim 1 , wherein AA 1 , AA 2 , AA 3 , AA 4 , AA 5 , AA 6 , AA 7 , AA 8 , and AA 9 is selected from any one of SEQ ID NOS: 64-99, 102-118, and 120-146.